The emergence of genomic technologies in 1990’s had a tremendous impact on global pharmaceutical and biotech organizations, as these technologies found wide ranging application in their in-house research. We have been a key innovator and through our subsidiary, Gene Logic, we have also been one of the earliest industry adopters of genomic technologies, knowledge databases, discovery platforms since then and continue to do so as the field of genomics rapidly advances. This has helped us develop the infrastructure and expertise to provide the widest range of genomic services which we are now able to offer to global pharmaceutical, biotech and research organizations.
We believe in sustained innovation, which is reflected through our key scientific patents and publications in priority areas like gene expression profiling, pattern discovery, biological data management & analysis. We work closely with regulatory bodies such as FDA and Institutional Review Board (IRB) to assess the application of quality control metrics and data standards.
Ocimum has built processes and systems that help us deliver the highest-quality and reproducible data available. Typically this optimization comes with a price, that is, lack of flexibility. However, that is not true at Ocimum. Our internal research programs challenged the lab with new sample types and limited RNA amounts. Samples were provided from multiple sites under timelines that kept changing. We built our system to handle these issues. We have an on-site biorepository, we painlessly accumulate samples until they are ready. We have developed and validated protocols to process challenging sample types that include FFPE samples and have unrivalled experience of running samples on varied platforms such as Affymetrix, Agilent, Illumina and ABI TaqMan. We understand that our customers’ requirements are unique and design customized and flexible solutions for them.
We are the acknowledged leader in providing high quality genomic data. Our laboratories generate data that is the reference standard used by major pharmaceutical companies. The Federal Drug Agency (FDA) is using data generated by us as their reference standard.
Our data quality is derived from extensive experience and a focused commitment to meet the needs of our internal target discovery and biomarker development teams. We have processed hundreds of sample types across thousands of arrays, we compared results across samples and across batches. We modified techniques and determined quality metrics at each processing stage. Our bioinformaticians reviewed the final data to determine successful processes. We meticulously detail all our activities, constantly learning and validating approaches. This multi-year commitment enabled us to define an unmatched collection of success parameters. Our Quality Assurance programs validate that the established procedures and protocols were followed and that QC metrics have been determined. New methods undergo rigorous testing and their results are compared to previous work before the method is certified. That’s why we have the best data quality.
Our subsidiary, Gene Logic started running genomic platforms over 12 years ago for our own target discovery and biomarker development programs. In addition to being one of Affymetrix’s first clients, we were asked and agreed to help co-develop an array with them. Since that start, we have successfully processed hundreds of sample types from FFPE to whole blood. We have run samples on over two hundred thousand arrays! We have completed hundreds of data analysis projects for our clients. We are GLP compliant and have run many successful clinical trials. External audits by clients have confirmed our compliance.
Gene Logic |
